45-65 years of age. The age specific incidence rates increase sharply with every ten years rise after the age of 35 years. The factors associated with an increased risk include older age, race (white), nulliparity, and family history of ovarian, endometrial, or breast cancer. 3 Ovarian cancer is often asymptomatic or present with a variety of vague symptoms like pelvic or abdominal pain, bloating, poor appetite, urinary urgency. So, the high mortality rate of ovarian cancer is due to asymptomatic and indolent growth of the tumor, delayed onset of symptoms, and lack of proper screening that results in its diagnosis in the advanced stages.
INTRODUCTION
Adnexal masses are a common cause for admission of patients to gynaecology clinics, and one of the most common reasons for referral to gynaecologic oncology departments for possibility of uterine or ovarian malignancies. The most prevalent type adnexal masses is ovarian masses, which vary from benign cysts to malignant ovarian cancers. Ovarian cancer ranks third after cervical and uterine cancer among gynecological malignancies. 1 It also has worst prognosis and the highest mortality rate. Ovarian cancer constitutes 3 rd most common cancer and contributes to about 6% of total cancer cases among the Indian women. 2 The mean AAR (age adjusted rate) was observed to be 5.3 per 100,000 populations. About 50% of the total cases occurs between in deciding clinical management and surgical planning. Early identification of ovarian carcinomas and referral to a gynaeco-oncologist can facilitate accurate staging of the disease and optimal cyto-reductive treatment, enhancing patient survival. 4 Several diagnostic methods for adnexal masses have been reported, such as abdominal and transvaginal ultrasonography, three-dimensional ultrasound, color doppler ultrasonography and tumor markers. 5 However, none of these methods used individually has shown significantly better performance in detecting malignant tumors from clinically restricted ovarian masses. Treatment efficiency in patients with ovarian cancers could be increased by standardization of preoperative evaluation. A formula-based scoring system known as risk of malignancy index (RMI) was introduced by Jacobs et al. 6 in 1990, which was termed RMI. 1 It is a product of ultrasound findings (U), the menopausal status (M) and serum CA-125 levels. (RMI = U × M × CA-125).
RMI was modified in 1996 by Tingulstad et al, as RMI 2 and again in 1999 known as RMI 3.8 The difference between the three indices lies in the different scoring of ultrasound findings and menopausal status. 7 The three versions of RMI have been confirmed retrospectively and prospectively in different clinical studies, where a cut off value of 200 for RMI revealed the best discrimination between benign and malignant adnexal mass, because of its high sensitivity and specificity levels. 9 Subsequently, RMI 4 was introduced by Yamamoto et al in 2009, which included tumor size as an additional parameter. 10 The objective of the present study was to evaluate the performance of RMI 3 in preoperative discrimination of benign and malignant adnexal masses and its applicability in daily clinical practice.
METHODS
The study was a prospective study, carried out in all patients admitted with adnexal masses to the obstetrics and gynecology department of M.K.C.G Medical College, Berhampur, India between September 2017 to August 2019.
A total of 130 patients were studied and data related to age, parity, menstrual history, family history of cancer, symptoms at diagnosis were abstracted.
Inclusion criteria
• Only women who underwent surgical treatment were included in this study as histopathological examination was taken as gold standard to calculate the accuracy of RMI.
Exclusion criteria
• Women receiving chemotherapy due to ovarian cancers, masses arising from urinary tract and gastrointestinal tract, ectopic pregnancy were excluded from the study.
Detailed history, pelvic and physical examination, serum CA 125 levels, abdominal ultrasound findings and menopausal status of all cases were recorded. Ultrasound scan was performed by expert radiologists.
The modified RMI (RMI 3) for each woman was calculated using the formula:
The ultrasound findings were evaluated and one point was given for each: multilocularity, bilaterality, presence of solid areas, presence of ascitis or presence of intraabdominal metastases. A zero or one point gives U = 1 and total of 2 or more points gives U = 3. Patients with amenorrhea more than a year or who had hysterectomy and older than 50 years were described as postmenopausal women and they scored M = 3. Other patients scored M = 1. The absolute values of serum CA 125 (U/mL) was entered directly in the formula. The levels of < 35 U/mL were considered to be normal. Histopathologic diagnosis regarded as a gold standard for evaluation of results.
Statistical analysis
All statistical analysis were done using SPSS version 25 (IBM) and Microsoft Excel 2016 for windows. The t-test for the means and Chi square test was used to compare the differences in distribution of age, menopausal status, ultrasonographic score and other discrete variables. A probability value of p < 0.05 was considered to be statistically significant. The sensitivity, specificity, positive (PPV), and negative (NPV) predictive values with reference to the presence of malignant and benign disease were calculated. Receiver operating characteristics (ROC) curves of RMI were plotted to determine the appropriate cut-off value for discriminating between benign and malignant adnexal masses.
RESULTS
According to the histopathological examination of surgical specimens, 85 (65.4%) were benign and 45 (34.6%) were malignant. The most frequent benign conditions included serous cystadenoma (n = 25) and dermoid cyst (n = 85). Majority of malignant tumors were epithelial origin with predominant types being papillary serous cystadenocarcinoma (n = 15) ( Table 1 ). Most of the women presented with age group of 40-59 years i.e. 57 (43.8%) ( Table 2 ).
The distribution of age, menopausal status, ultrasound score, CA125 levels and RMI are summarized in Table 3 . Mean age of patients with malignant adnexal mass (47.89±14.12 years) was significantly higher than mean Majority of women presented with pain abdomen (55.4%) followed by mass abdomen with pain abdomen (46.2%). Majority of the women were multiparous 86 (66.2%). Analysis of 130 patients with ultrasound features revealed that presence of solid areas, presence of ascitis and metastasis showed significant correlation with p < 0.05. Bilaterality and multilocularity in predicting malignancy failed to be proved significant in our study with p value > 0.05. 62.3% (81) cases had an ultrasound score of 1, of which 72 had benign, while 9 had malignant diseases. Out of 37.6% (49) patients with score 3, 13 had benign and 36 had malignant diseases. Ultrasound score of 3 was statistically significant for malignant masses (p < 0.001). The diagnostic performance of RMI-3 > 225, against CA-125 level > 35, ultrasound score of 3 and menopausal score of 3 is compared in Table 5 . Among the criteria RMI score > 225 has highest sensitivity, specificity, PPV, NPV and diagnostic accuracy, when compared with individual parameters. Among the individual parameters, USG score of 3 has the highest sensitivity, specificity, PPV, NPV and diagnostic accuracy (80%, 84.7%, 73.5%, 88.9% and 83.1% respectively).
DISCUSSION
The present study has established the effectiveness of RMI in assessment of women with adnexal masses, particularly in low-resource settings. Some of the potential advantages of RMI include rapid triage of patients and timely referral to gynaec oncologists, thereby avoiding suboptimal primary surgeries at local hospitals or peripheral centres. In the present study commonest age group was 40-59 years which was consistent with previous studies, which showed that the disease was more prevalent in this age group (mean 50 years). [11] [12] [13] In our study mean age of benign group was 37.41±12.66 years and mean age of malignant group was 47.89±14.12 years which coincides with study of Ashrafgangooei et al and Simsek et al who revealed mean age in benign as 37.0±8.79, 35.23±10.87 and 50.8±12.9, 50.78±13.39 in malignant group respectively. 14, 15 The chances of ovarian malignancy increases with the increasing age.
A total 64.4% of malignancies occurred in postmenopausal women and 35.6% among premenopausal women. This was in agreement with Rao JH et al, and Kumari N et al, showing similar incidence rates and preponderance in postmenopausal patients. 16, 17 Ultrasonography has been widely used for evaluation of adnexal masses. In our study, an ultrasound score of 3 had the sensitivity 80%, specificity 84.7%, positive predictive value 73.5% and negative predictive value (88.9%) which is in agreement with Vasudevan et al. 18 We got higher sensitivity and specificity than others because USG were done by expert radiologist in majority of our cases.
Serum CA 125 level is universally used as a tumor marker for diagnosing ovarian cancer, though other gynecological pathology can also increase its levels.
Simsek et al reported a sensitivity of 78.6% and specificity of 63.5% for CA-125 > 35 U/ml. 15 Recent study by 2018 Singhal S et al gave a sensitivity of 75% and specificity of 90% for CA-125 levels > 35U/ml. 19 In our study, CA125 levels ≥ 35 U/ml had a sensitivity of 75.6%, the specificity of only 48.2%, PPV 43.6% and NPV of 78.8%. A higher prevalence of pelvic inflammatory diseases and endometriosis might have contributed to elevated CA125 levels in the majority of our patients along with fluctuation of CA125 during the menstrual cycles in premenopausal patients with adnexal masses and its more specificity for non-mucinous epithelial ovarian tumor might be the reason for its low diagnostic performance in the detection of malignant ovarian disease.
The RMI cut-offs in many studies ranged from 25 to 250 (reviewed in Geomini et al). 20 Most studies reported an increased diagnostic accuracy and performance with an RMI cut-off of 200. 6 Our study confirmed that RMI 3 was reliable in preoperative discrimination between malignant and benign adnexal masses at cut off value of 200. It yielded sensitivity of 75.5%, specificity of 96.4%, PPV of 91.89%, NPV of 88.17% and accuracy of 86.92% at cut off value of 200. A systematic review study by Geomini et al, 116 diagnostic studies for adnexal malignancy was reviewed. 20 The reported result showed that RMI at cutoff point of 200 had a sensitivity of 78% and a specificity 87% for malignant mass diagnoses which was similar to our results.
The best performance in our study obtained for RMI-3 was at the cut-off point 225 with highest area under the ROC curve i.e., AUC = 87%, and high sensitivity of 75.55%, specificity of 98.82% PPV of 97.14%, NPV of 88.42%, and accuracy of 90.76% which were comparable to the majority of earlier reports that employed a similar cut-off. Our results for RMI were in agreement with the results from other studies in which RMI was suggested to be better than other single parameters, with the highest area under the curve. The present study is compared with
